Breaking News Bar

Business News and Information

Edge Therapeutics Reports First Quarter 2018 Financial Results

BERKELEY HEIGHTS, N.J., May 01, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE) today announced financial results for the quarter ended March 31, 2018.

First Quarter Financial Results

Cash Position: Cash, cash equivalents and marketable securities as of March 31, 2018 were $75.0 million, compared with $88.1 million as of December 31, 2017. Information on Edge’s ongoing financial obligations and working capital can be found in Edge’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.

Operating Expenses:  Research and development (R&D) expenses were $12.7 million in the first quarter of 2018, compared to $7.6 million in the first quarter of 2017. The increase in R&D expense was primarily due to an increase in external expenses related to EG-1962 clinical development, and estimated study close down costs for the NEWTON 2 study. General and administrative (G&A) expenses were $4.7 million for the three months ended March 31, 2018, compared to $4.2 million in the comparable period in 2017. The increase in G&A expense was largely due to increases in personnel-related costs, legal fees, professional fees and marketing costs.

Net Loss: Net loss of $20.8 million for the first quarter ended March 31, 2018 included non-cash impairment charges of $2.7 million related to the write-down of machinery and equipment, and compared to net loss of $12.2 million for the comparable period in 2017.

Review of Strategic Alternatives

On April 30, 2018, Edge announced that its Board of Directors is conducting a comprehensive review of strategic alternatives focused on maximizing stockholder value. In conjunction with the exploration of strategic alternatives, Edge intends to streamline its operations in order to preserve its cash resources. Edge has retained Piper Jaffray & Co. to act as its financial advisor to assist with this review process. Potential strategic alternatives that may be explored or evaluated as part of this review include, but are not limited to, an acquisition, merger, business combination or other strategic transaction involving Edge.

There is no defined timeline for completion of the review process. There is no assurance that this review will result in Edge pursuing any transaction or that a transaction, if pursued, will be completed. Edge does not intend to discuss or disclose further developments regarding the strategic review process unless and until its Board of Directors has approved a specific action or otherwise determined that further disclosure is appropriate or required by law.

About Edge Therapeutics, Inc.
Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms for the management of acute, life-threatening conditions. For additional information about Edge, please visit

Forward-Looking Statements
This press release and any statements of representatives of Edge Therapeutics, Inc. related thereto that are not historical in nature contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, without limitation, statements with respect to Edge’s plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," “seeks,” "intends," "plans," "potential" or similar expressions, including statements with respect to the potential effects of its products and plans to assess and undertake next steps for the company. These statements are based upon the current beliefs and expectations of Edge’s management and are subject to significant risks and uncertainties. Actual results may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various risk factors (many of which are beyond Edge's control) as described under the heading "Risk Factors" in Edge’s filings with the United States Securities and Exchange Commission.

Investor and Media Contact:
Gregory Gin
Edge Therapeutics, Inc.
Tel: 1-800-208-EDGE (3343)

Statements of Operations and Comprehensive Loss
 Three Months Ended March 31,
 2018  2017 
Operating expenses:   
Research and development expenses$12,742,085  $7,589,496 
General and administrative expenses 4,681,516   4,201,842 
Impairment charges 2,672,581   - 
Total operating expenses 20,096,182   11,791,338 
Loss from operations (20,096,182)   (11,791,338) 
Other income (expense):       
Interest income 246,639   96,259 
Interest expense (990,560)   (475,141) 
Net loss and comprehensive loss$(20,840,103)  $(12,170,220) 
Loss per share basic and diluted$(0.67)  $(0.42) 
Weighted average common shares outstanding basic and diluted 30,965,874   28,998,616 


Balance Sheets
 March 31, 2018 December 31, 2017
Current assets:   
Cash and cash equivalents$74,996,609  $88,067,647 
Prepaid expenses and other current assets 917,065   986,680 
Total current assets 75,913,674   89,054,327 
Property and equipment, net 552,757   3,423,880 
Other assets 142,870   142,870 
Total assets$76,609,301  $92,621,077 
Current liabilities:     
Accounts payable$2,957,284  $4,369,133 
Accrued expenses 8,472,881   5,422,205 
Short term debt 20,900,000   3,075,421 
Total current liabilities 32,330,165   12,866,759 
Noncurrent liability:     
Long term debt -   17,382,907 
Preferred stock, 5,000,000  shares authorized at March 31, 2018 and December 31, 2017, 0 outstanding -   - 
Common stock, $0.00033 par value, 75,000,000 shares authorized at March 31, 2018 and December 31, 2017, 31,246,231 shares and 30,869,205 shares issued and outstanding at March 31, 2018 and  December 31, 2017, respectively 10,524   10,400 
Additional paid-in capital 217,057,074   214,309,370 
Accumulated deficit (172,788,462)   (151,948,359) 
Total stockholders' equity 44,279,136   62,371,411 
Total liabilities and stockholders' equity$76,609,301  $92,621,077 

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear